既往经直肠超声引导活检阳性患者行磁共振腔内引导前列腺活检的病理结果与漏诊癌症预测因素
回顾性分析40例既往经直肠超声引导活检阳性且低/中危前列腺癌患者,行3T多参数MRI及腔内MRI引导活检,总体癌症检出率65%,40%病例疾病分级升级,漏诊率35%且前列腺体积>40mL更高、前部腺体更低。
要点
- 腔内MRI引导活检在65%患者中检出癌症,40%病例出现疾病分级升级。
- 漏诊癌症(假阴性率35%)在前列腺体积>40mL时更高,前部腺体位置更低。
- 既往经直肠超声阳性位点仅80%在MRI可见,20%无影像对应。
核心结论
- 既往经直肠超声引导活检阳性后行确认性腔内MRI引导活检可导致高疾病升级率,从而改善疾病风险分层,尤其考虑主动监测或局灶治疗时。
研究设计与样本
- 回顾性评估2012至2016年一所大学医院50例连续男性患者,排除10例经直肠超声活检后接受治疗者,最终纳入40例(平均年龄63岁,范围47-84岁),平均时间间隔11个月。
- 所有患者行多参数3T MRI(T2加权、扩散加权和动态对比增强)及经直肠腔内MRI引导活检。
关键影像表现/征象
- 71个经直肠超声阳性六分仪活检位点中,80%(57/71)在MRI可见,20%(14/71)无影像对应。
- 腔内MRI引导活检对可见位点的阳性率为52.6%(30/57)。
诊断标准与关键数值
- 总体癌症检出率为65%(26/40)。
- 腔内MRI引导活检检出14个既往未发现癌灶,其中临床显著癌(CSC)占57.1%(8/14)。
- 总体疾病升级率40%(16/40),在腔内MRI引导活检阳性病例中为61.5%(16/26);1例从Gleason评分3+4=7降级为3+3=6。
- 对检测到的病灶,腔内MRI引导活检升级60%(18/30)、降级3.3%(1/30)。
- 假阴性率35%,其中14.2%(2/14)患者为临床显著癌(Gleason评分≥7);前列腺体积>40mL时假阴性率更高(P=.04),前部腺体位置更低(P=.01)。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate the role of confirmatory in-bore MRI-guided biopsy in patients with low- or intermediate-risk disease diagnosed at prior transrectal US-guided biopsy and to evaluate the rate and predictors for missed cancers.
MATERIALS AND METHODS: A retrospective evaluation of 50 consecutive men who had previously undergone transrectal US-guided biopsy with positive results and who underwent subsequent in-bore MRI-guided biopsy at our university hospital (average time interval, 11 months) between 2012 and 2016 was performed. Ten men were excluded because of a history of treatment after transrectal US-guided biopsy. A total of 40 men (mean age, 63 years; range, 47-84 years) were included in this study. Multiparametric 3-T MRI (T2-weighted, diffusion-weighted, and dynamic contrast material-enhanced) and transrectal in-bore MRI-guided biopsy were performed. Cancer detection, disease-grade changes, and cancers missed at in-bore MRI-guided biopsy were evaluated. Descriptive statistics were used to report different rates. The Fisher exact test was used for categoric variables. The Mann-Whitney U test and independent Student t test were used for nonparametric and parametric data, respectively. The McNemar test was used for paired data.
RESULTS: The overall cancer detection rate when using in-bore MRI-guided biopsy was 65% (26 of 40). In-bore MRI-guided biopsy detected 14 previously undiscovered cancerous lesions (clinically significant cancers [CSCs], 57.1% [eight of 14]). An overall disease upgrade by in-bore MRI-guided biopsy occurred in 40% (16 of 40) of cases (61.5% [16 of 26] of cases with positive results from in-bore MRI-guided biopsy). One case was downgraded from a Gleason score (GS) of 3 + 4 = 7 to a GS of 3 + 3 = 6. Out of 71 sextant biopsies with positive results detected by transrectal US-guided biopsy (from all 40 patients), 80% (57 of 71) were visible on MR images (in-bore MRI-guided biopsy results were positive in 52.6% [30 of 57]), and 20% (14 of 71) had no image correlates on MR images. In-bore MRI-guided biopsy upgraded 60% (18 of 30) and downgraded 3.3% (one of 30) of detected lesions. The false-negative rate was 35% (14.2% [two of 14] of patients had CSCs; GS ≥ 7), was higher in prostate volumes of greater than 40 mL, and was lower in the anterior gland location (P = .04 and .01, respectively).
CONCLUSION: Performing confirmatory in-bore MRI-guided biopsy following positive transrectal US-guided biopsy resulted in a high disease-upgrade incidence with subsequently improved disease-risk stratification, particularly when considering patients for active surveillance or focal therapy. Supplemental material is available for this article. © RSNA, 2020See also the commentary by Weiss and Solomon in this issue.
引用
- Elfatairy KK, Filson CP, Sanda MG, et al. In-Bore MRI-guided Prostate Biopsies in Patients with Prior Positive Transrectal US-guided Biopsy Results: Pathologic Outcomes and Predictors of Missed Cancers. Radiol Imaging Cancer. 2020. PMID: 33033806. doi:10.1148/rycan.2020190078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。